We carefully read the recent study by Liu et al on the effectiveness of tofacitinib for refractory Behçet’s syndrome (BS).1 In total, 13 patients with BS were enrolled, including 5 cases with vascular involvement, 7 with gastrointestinal (GI) ulcers and one suffering polyarthritis. As an add-on approach, tofacitinib improved the outcomes in all patients with vascular lesions, but unchanged or worsened in 5/7 GI involvement cases. Their observation give support to the hypothesis that BS is not an independent disease, but a heterogeneous and multisystemic complex syndrome.2 Different major organ involvements, vascular and GI involvement could link to its unique underlying immunopathological mechanisms, which led to radical treatment responses.3 In their study, the only manifestation of ocular involvement was scleritis in one patient with polyarthritis, which is not a specific ophthalmological feature of BS. Notably, uveitis is one of the specific features of ocular involvement in patients with BS,4 which may lead to visual loss in up to 25% of patients in spite of biological agents.5 Here, we reported the efficacy and safety profile …

中文翻译：

---

关于“托法替尼治疗难治性白塞氏综合征的初步研究”的通讯

我们仔细阅读了Liu等人最近关于托法替布治疗难治性白塞氏综合征（BS）有效性的研究。1总共入组了13名BS患者，其中5例有血管受累，7例有胃肠道（GI）溃疡，1例有胃肠道（GI）溃疡。患有多关节炎。作为一种附加方法，托法替布改善了所有血管病变患者的预后，但在 5/7 胃肠道受累病例中没有变化或恶化。他们的观察支持了这样的假设：BS 不是一种独立的疾病，而是一种异质性、多系统的复杂综合征。2 不同的主要器官受累、血管和胃肠道受累可能与其独特的潜在免疫病理学机制有关，从而导致彻底的治疗反应。3在他们的研究中，一名多关节炎患者眼部受累的唯一表现是巩膜炎，这并不是 BS 的特定眼科特征。值得注意的是，葡萄膜炎是 BS 患者眼部受累的具体特征之一，4 尽管使用生物制剂，仍可能导致高达 25% 的患者视力丧失。5 在此，我们报告了疗效和安全性概况……